

CRO Communiqué
Keeping you informed about CRO progress
April 2013

Top Enrolling Physicians for March 2013

| Physician | Patient Registrations | Treatment Credits | Control Credits | Total Credits |
|----------------|-----------------------|-------------------|-----------------|---------------|
| Dr. Biggers | 1 | 0 | 1 | 1 |
| Dr. Bonebrake | 2 | 2 | 0.5 | 2.5 |
| Dr. Carlson | 8 | 1.6 | 5.5 | 7.1 |
| Dr. Ellis | 1 | 0 | 1 | 1 |
| Dr. Gillett | 1 | 0 | 1 | 1 |
| Dr. Hassan | 1 | 1 | 0 | 1 |
| Dr. Raju | 2 | 1 | 1 | 2 |
| Dr. Shunyakov | 2 | 2 | 0 | 2 |
| Dr. Tiriveedhi | 1 | 0 | 1 | 1 |
| TOTALS | 19 | 7.6 | 11 | 18.6 |

We earned 7.6 treatment credits and 11.1 control credits this month. With two months left in this grant year, we have earned 78 treatment credits and 85.4 control credits. Good news is we have exceeded our NCI target for control credit for this grant year of 80. YEA! However, we need to earn 32 treatment credits to meet the NCI target of 110 for the year. Combining treatment and control credits at this time, we are 5 credits ahead to be on target to meet our NCI targets. This is great! Thanks to all of you for placing your patients on clinical trials.

NCI's CIRB

CRO is working to collaborate with the NCI Central Intuitional Review Board. The Central IRB (CIRB) Initiative is designed to help reduce the administrative burden on local IRBs and investigators while continuing a high level of protection for human research participants. CIRB enables an investigator to enroll patients into NCI-sponsored clinical trials significantly faster than when employing a traditional IRB review. The CIRB Initiative is sponsored by NCI in consultation with the Department of Health and Human Services Office for Human Research Protections (OHRP). We are expecting to hear that our application to join the CIRB has been accepted and we have been granted access to CIRB studies at any time. Once we receive access we will begin using the CIRB for phase III NCI studies. We are also working with the Mercy Springfield IRB as they transition to cover CRO IRB needs for Mercy St. Louis, Mercy Joplin and Good Samaritan.

New CRO Affiliations

Much work is being done at CRO in preparation for Mercy St. Louis and Good Samaritan in Mt. Vernon, Illinois to become CRO affiliates. May 31, 2013 is the date for this transaction to officially take place.

New CRO Principal Investigator

The CRO Executive Board is in process of interviewing candidates for the a new CRO Principal Investigator position. We hope to announce the new investigator within a couple of weeks.

CRO Steering Committee Meeting

Our next CRO Steering Committee will be Monday, April 22nd 3rd at TOUCH Restaurant. Dr. Joseph Kim MD, a board certified surgical oncologist, currently serving as Associate Professor of Surgery and Director of Surgical Oncology Fellowship Program at City of Hope National Medical Center in California, will speak on "New Approval in Metastatic Colorectal Cancer (mCRC): A Case-Based Approach". Dr. Kim is on the Editorial Board of "World Journal of GI Surgery" and an invited reviewer of many national and international journals. Some of Dr. Kim's current major research projects are:

- Mechanisms of pancreatic intraepithelial neoplasia & pancreatic cancer metastasis & progression
- Investigation of racial & ethnic disparities in GI cancers
- Molecular marker analysis of solid tumors
- Evaluation of RET G691S polymorphism in GI malignancies

Please RSVP to (417) 269-4520 by Thursday, April 18, 2013 to attend.

New Studies Approved in March 2013
Opened at Cox and Mercy Springfield

No new studies were opened this month.

Studies Permanently Closed to Enrollment at Cox & Mercy in March 2013

CALGB 90802 Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors

NCCTG N10C1 Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo-Controlled Trial

NSABP DMP-1 A Study to Evaluate Different Decision-Making Approaches Used by Women Known to be at Increased Risk for Breast Cancer

GOG 0249 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Cancer

SWOG S0927 A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness in Women with Early Stage Breast Cancer, Phase III

Studies Temporally Closed to Enrollment at Cox & Mercy in March 2013

RTOG 0436 A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery